Pardridge W M, Van Herle A J, Naruse R T, Fierer G, Costin A
J Biol Chem. 1983 Jan 25;258(2):990-4.
The in vivo kinetics of hepatic clearance of 125I-asialo-orosomucoid and 125I-asialofetuin was determined with a portal vein injection technique in barbiturate-anesthetized rats. Nonlinear regression analyses of saturation data gave the following parameters for asialo-orosomucoid, Km = 0.26 +/- 0.06 mg/ml, Vmax = 320 +/- 70 micrograms/min/g, and for asialofetuin, Km = 0.32 +/- 0.07 mg/ml, Vmax = 240 +/- 40 micrograms/min/g. Unlabeled asialofetuin inhibited the clearance of 125I-asialo-orosomucoid with a Ki = 0.25 +/- 0.04 mg/ml. Based on a model assuming that in vivo receptor concentration much greater than receptor KD, then the maximal binding capacity of the external surface of liver cells in vivo for asialo-orosomucoid is 2Km or 520 micrograms/ml or 52 micrograms/g of liver, assuming the liver interstitial space is 0.1 ml/g. Our estimate of in vivo binding capacity approximates in vitro estimates of total hepatic binding capacity, but is 10-fold greater than in vitro estimates of binding capacity on the external surface of liver cells. These results suggest the large majority of asialoglycoprotein receptors are located on the external surface of liver cells. The saturability of 125I-asialo-orosomucoid clearance was also demonstrated with a portal vein double bolus technique, wherein the portal injection of 20-1000 micrograms of unlabeled asialo-orosomucoid was followed 30 s later by the portal injection of tracer. Maximal inhibition of uptake was obtained with a portal vein injection of greater than or equal to 500 micrograms of asialo-orosomucoid. The specific extraction of the 125I-asialo-orosomucoid, which was near zero shortly after a 400-micrograms loading dose, gradually increased toward normal levels with a t1/2 of 21 min. This t1/2 may represent the in vivo rate of receptor recycling, since the gradual increase in unoccupied receptor sites is consistent with the model of receptor binding, internalization, and recycling.
采用门静脉注射技术,在巴比妥麻醉的大鼠体内测定了125I-去唾液酸血清类黏蛋白和125I-去唾液酸胎球蛋白的肝脏清除动力学。对饱和数据进行非线性回归分析,得出以下去唾液酸血清类黏蛋白参数:Km = 0.26±0.06mg/ml,Vmax = 320±70μg/min/g;去唾液酸胎球蛋白的参数为:Km = 0.32±0.07mg/ml,Vmax = 240±40μg/min/g。未标记的去唾液酸胎球蛋白抑制125I-去唾液酸血清类黏蛋白的清除,Ki = 0.25±0.04mg/ml。基于一个假设体内受体浓度远大于受体解离常数(KD)的模型,假设肝间质空间为0.1ml/g,那么体内肝细胞外表面对去唾液酸血清类黏蛋白的最大结合能力为2Km,即520μg/ml或52μg/g肝脏。我们对体内结合能力的估计接近肝脏总结合能力的体外估计值,但比肝细胞外表面结合能力的体外估计值大10倍。这些结果表明,绝大多数去唾液酸糖蛋白受体位于肝细胞外表面。采用门静脉双推注技术也证明了125I-去唾液酸血清类黏蛋白清除的饱和性,即在门静脉注射20 - 1000μg未标记的去唾液酸血清类黏蛋白30秒后,再进行门静脉注射示踪剂。门静脉注射≥500μg去唾液酸血清类黏蛋白可获得最大摄取抑制。在400μg负荷剂量后不久,125I-去唾液酸血清类黏蛋白的特异性摄取接近零,随后以21分钟的半衰期逐渐增加至正常水平。这个半衰期可能代表体内受体循环的速率,因为未占据受体位点的逐渐增加与受体结合、内化和循环的模型一致。